| 摘要: |
| 心力衰竭是一种复杂的临床综合症,在全球具有较高的发病率和死亡率。良好的生物标志物有助于疾病的危险分层和预后评估。目前利钠肽是唯一的生物标志物被录入心力衰竭的指南。近年来多种与心力衰竭病理过程相关的生物标志物相继出现,与纤维化相关的、与心肌细胞损伤相关的、与细胞基质重塑相关的等,这些生物标志物对心力衰竭的筛查鉴别以及疾病危险分层和预后评估都有一定的价值,本文将对这些生物标志物的进行总结分析。 |
| 关键词: 心力衰竭 生物标志物 临床应用 危险分层 预后评估 |
| DOI:10.13506/j.cnki.jpr.2020.11.012 |
| 基金项目: |
|
Publication Date:November 25, 2020
|
|
| Latest research progresss in biomarkers of heart failure |
|
| () |
| Abstract: |
| Heart failure is a complex clinical syndrome with high incidence rate and mortality worldwide. Good biomarkers are helpful for risk stratification and prognosis assessment. At present, natriuretic peptide is the only biomarker to be entered into the guidelines of heart failure.In recent years,a variety of biomarkers related to the pathological process of heart failure have emerged one after another, which are related to fibrosis,myocardial cell injury,matrix remodeling and so on.These biomarkers have certain value for screening and differentiation of heart failure, disease risk stratification and prognosis evaluation. This paper summarized and analyzed these biomarkers. |
| Key words: Heart failure Biomarker Clinical application Risk stratification Prognosis evaluation |